Cargando…

109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile

BACKGROUND: Decreases in multidrug-resistant organism (MDRO) colonization and antibiotic resistance gene abundance have been reported after fecal microbiota transplantation (FMT), but data on clinical microbiology culture and susceptibility results after FMT are limited. METHODS: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodworth, Michael, Wang, Tiffany, Raheja, Divyanshu, Waldman, Alex, Friedman-Moraco, Rachel, Graham, Allen, Dhere, Tanvi, Kraft, Colleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253011/
http://dx.doi.org/10.1093/ofid/ofy209.000
_version_ 1783373397860810752
author Woodworth, Michael
Wang, Tiffany
Raheja, Divyanshu
Waldman, Alex
Friedman-Moraco, Rachel
Graham, Allen
Dhere, Tanvi
Kraft, Colleen
author_facet Woodworth, Michael
Wang, Tiffany
Raheja, Divyanshu
Waldman, Alex
Friedman-Moraco, Rachel
Graham, Allen
Dhere, Tanvi
Kraft, Colleen
author_sort Woodworth, Michael
collection PubMed
description BACKGROUND: Decreases in multidrug-resistant organism (MDRO) colonization and antibiotic resistance gene abundance have been reported after fecal microbiota transplantation (FMT), but data on clinical microbiology culture and susceptibility results after FMT are limited. METHODS: We retrospectively reviewed the available microbiology results for patients who underwent FMT for recurrent Clostridioides difficile infection (RCDI) at Emory University from July 7, 2012 until December 2017 and had microbiology results within 1 year pre- and post-FMT. Demographic and clinical characteristics were abstracted by trained reviewers, and statistical tests of differences in central tendency were tested with Wilcoxon signed-rank tests. RESULTS: Of 236 unique patients undergoing FMT during the study period, 18 had growth of Gram-negative bacteria on culture pre- and post-FMT. Of these, 8 had Gram-negative growth in urine culture (the most common site) pre- and post-FMT. Fourteen (14/18, 78%) patients were female, 4/18 (22%) were black, 14/22 (78%) were white, and 18/18 (100%) were non-Hispanic. The mean number of CDI episodes prior to first FMT was 4 (range 3–7 episodes). Differences in counts of susceptible, intermediate, and resistant susceptibility test results before and after FMT are shown in Figures 1 and 2. Although a trend in reduction of resistant reports is visually suggested, this was not statistically significant by Wilcoxon signed-rank testing (P = 0.10 for all cultures, P = 0.21 for urine). Ten patients had pre-FMT micro results and no micro results after FMT, but reduction of count of infectious syndromes in FMT could not be tested with this study design. Abstraction of viral quantitative PCR results did not suggest clinical recognition of new infection or reactivation of viruses after FMT. CONCLUSION: FMT may reduce clinical burden of antimicrobial resistance, but statistically significant differences in resistance were not detected in this study. Further study with RCTs is needed. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253011
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62530112018-11-28 109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile Woodworth, Michael Wang, Tiffany Raheja, Divyanshu Waldman, Alex Friedman-Moraco, Rachel Graham, Allen Dhere, Tanvi Kraft, Colleen Open Forum Infect Dis Abstracts BACKGROUND: Decreases in multidrug-resistant organism (MDRO) colonization and antibiotic resistance gene abundance have been reported after fecal microbiota transplantation (FMT), but data on clinical microbiology culture and susceptibility results after FMT are limited. METHODS: We retrospectively reviewed the available microbiology results for patients who underwent FMT for recurrent Clostridioides difficile infection (RCDI) at Emory University from July 7, 2012 until December 2017 and had microbiology results within 1 year pre- and post-FMT. Demographic and clinical characteristics were abstracted by trained reviewers, and statistical tests of differences in central tendency were tested with Wilcoxon signed-rank tests. RESULTS: Of 236 unique patients undergoing FMT during the study period, 18 had growth of Gram-negative bacteria on culture pre- and post-FMT. Of these, 8 had Gram-negative growth in urine culture (the most common site) pre- and post-FMT. Fourteen (14/18, 78%) patients were female, 4/18 (22%) were black, 14/22 (78%) were white, and 18/18 (100%) were non-Hispanic. The mean number of CDI episodes prior to first FMT was 4 (range 3–7 episodes). Differences in counts of susceptible, intermediate, and resistant susceptibility test results before and after FMT are shown in Figures 1 and 2. Although a trend in reduction of resistant reports is visually suggested, this was not statistically significant by Wilcoxon signed-rank testing (P = 0.10 for all cultures, P = 0.21 for urine). Ten patients had pre-FMT micro results and no micro results after FMT, but reduction of count of infectious syndromes in FMT could not be tested with this study design. Abstraction of viral quantitative PCR results did not suggest clinical recognition of new infection or reactivation of viruses after FMT. CONCLUSION: FMT may reduce clinical burden of antimicrobial resistance, but statistically significant differences in resistance were not detected in this study. Further study with RCTs is needed. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253011/ http://dx.doi.org/10.1093/ofid/ofy209.000 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Woodworth, Michael
Wang, Tiffany
Raheja, Divyanshu
Waldman, Alex
Friedman-Moraco, Rachel
Graham, Allen
Dhere, Tanvi
Kraft, Colleen
109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile
title 109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile
title_full 109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile
title_fullStr 109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile
title_full_unstemmed 109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile
title_short 109. Differences in Gram-Negative Antibiotic Susceptibility Among Patients Receiving Fecal Microbiota Transplant for Clostridioides difficile
title_sort 109. differences in gram-negative antibiotic susceptibility among patients receiving fecal microbiota transplant for clostridioides difficile
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253011/
http://dx.doi.org/10.1093/ofid/ofy209.000
work_keys_str_mv AT woodworthmichael 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile
AT wangtiffany 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile
AT rahejadivyanshu 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile
AT waldmanalex 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile
AT friedmanmoracorachel 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile
AT grahamallen 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile
AT dheretanvi 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile
AT kraftcolleen 109differencesingramnegativeantibioticsusceptibilityamongpatientsreceivingfecalmicrobiotatransplantforclostridioidesdifficile